Feb. 27, 2020: U=U perception vs. reality; frequency of incorrect self-reported viral load levels; how HIV transmission cluster predicts care continuum gaps; integrase inhibitor uptake and discontinuation.
Oral Arguments in Antitrust Case Against HIV Drug Companies Began Last Week. Plaintiff Peter Staley Explains the Case
The case could change the way pharma companies make agreements to keep generic versions of single-tablet pills at bay.
This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.
Although the painful joint condition was associated with early protease inhibitors (predominantly indinavir), a recent case report now links the condition to the integrase inhibitor elvitegravir/c (EVG/c).
An analysis from use of integrase inhibitors in clinical practice reported significantly higher rates of discontinuations related to side effects than seen in clinical studies and includes neurologial complications with dolutegravir.
Three posters at CROI 2015 showed new pediatric elvitegravir data. The posters described preliminary safety in the 6-to-12-year-old age group, and safety, efficacy, pharmacokinetics and resistance in 12-to-18 year olds receiving elvitegravir in fixed...
"If you're wondering what the big deal is [about the approvals of stand-alone cobicistat and elvitegravir], welcome to the club," Paul Sax, M.D., writes.
With this approval, each component of the single-tablet regimen Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir) is now green-lighted for use separately in HIV treatment regimens in the U.S.
Foster City, Calif. (Business Wire) -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company has received Complete Response Letters from the U.S. Food and Drug Administration (FDA) for its New Drug Applications (NDAs) for elvitegravir...
Richard Elion from Whitman-Walker Health in Washington presented updated 96 week results from the phase 3 head-to-head study of elvitegravir vs raltegravir.1
The 48 week results, first presented at the IAS conference in Rome last year showed elviteg...